ZEVTERA J Code: J0681

Drug & Product Overview

HCPCS Descriptor Injection, ceftobiprole medocaril sodium, 3 mg

HCPCS Added Date October 1, 2025

Manufacturer La Jolla Pharmaceutical Company

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Form Injection, Powder, For Solution

About ZEVTERA

Zevtera is a medication aligned to the HCPCS J Code: J0681 for billing, pricing, and reimbursement purposes in the United States. This Antibiotic medication is administered via the intravenous route and manufactured by La Jolla Pharmaceutical Company.

According to CMS Drug Use Information: Ceftobiprole is used to treat a variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. Showing 1 of 2 NDCs — log in for the full crosswalk.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
68547-0578-10	Zevtera	La Jolla Pharmaceutical Company	2224	667 MG
•••••-••••-•• Log in to view	ZEVTERA

Login to view 1 more NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

ZEVTERA Pricing & Reimbursement

J0681 Private Payer Reimbursement

$1.05 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

ZEVTERA CPT Administration Codes

CPT Code	Description
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

ZEVTERA Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Acute Bacterial Skin and Skin Structure Infections Community-Acquired Bacterial Pneumonia Staphylococcus aureus Bloodstream Infection (Bacteremia)

Drug Class

Cephalosporin Antibacterial [EPC]Cephalosporins [CS]Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]

Frequently Asked Questions

Is there an available Zevtera billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for ZEVTERA.

Are there any available Zevtera patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for ZEVTERA.

Where can I find Zevtera prescribing information?

Zevtera prescribing information can be found through the link below. Visit Here →

Where can I find Zevtera side effect information?

Our team has not yet identified a source of prescribing information for Zevtera.

Does billing Zevtera require wastage modifiers?

CMS does not include ZEVTERA (J0681) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J0681. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.